Drug
Elonva®
Elonva® is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_4
3
75%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 43 (100.0%)
Trials by Status
unknown125%
completed250%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_4
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
NCT06175832
completed
Corifollitropin Alfa and Embryo Morphokinetics
NCT04142190
completedphase_4
Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success
NCT02606500
unknownphase_4
Corifollitropin Alfa Versus Follitropin Beta in High Responders
NCT02471677
Clinical Trials (4)
Showing 4 of 4 trials
NCT06175832Phase 4
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
NCT04142190
Corifollitropin Alfa and Embryo Morphokinetics
NCT02606500Phase 4
Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success
NCT02471677Phase 4
Corifollitropin Alfa Versus Follitropin Beta in High Responders
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4